导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 18.53% | 320/4773 |
| 近一周 | -2.53% | 2477/5462 |
| 近一月 | -7.44% | 3827/5421 |
| 近一季 | -8.08% | 2673/5209 |
| 近半年 | 13.80% | 340/4920 |
| 近一年 | 23.47% | 316/4366 |
| 近两年 | 134.28% | 308/2954 |
| 近三年 | 87.37% | 199/2253 |
| 成立以来 | 75.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.87% 3442/4961 |
52.56% 534/5312 |
- - |
- - |
| 2025 | 41.90% 719/4813 |
3.18% 1167/3635 |
1.08% 2470/4076 |
41.03% 740/4524 |
-3.53% 3290/4813 |
| 2024 | 17.02% 738/3463 |
-6.13% 2013/2808 |
-0.75% 829/3014 |
15.20% 1789/3129 |
9.02% 353/3463 |
| 2023 | 3.52% 275/2656 |
27.61% 83/2280 |
-4.12% 1060/2385 |
-11.60% 2076/2515 |
-4.28% 950/2655 |
| 2022 | -29.35% 1596/2207 |
-22.11% 1683/1919 |
0.88% 1521/2016 |
-15.20% 1239/2113 |
6.03% 397/2208 |
| 2021 | 4.50% 574/1822 |
-7.02% 1052/1255 |
11.91% 357/1330 |
-8.10% 1102/1466 |
9.28% 123/1822 |
| 2020 | 19.98% 725/1250 |
-1.71% 227/1022 |
20.87% 256/1060 |
1.52% 1015/1152 |
- - |
| 2019 | 52.66% 88/1092 |
41.99% 34/748 |
-11.99% 775/797 |
10.64% 47/844 |
10.42% 130/912 |
| 2018 | -32.25% 526/834 |
- - |
- - |
- - |
-12.61% 464/691 |
| 2017 | -5.10% 508/714 |
- - |
- - |
- - |
- - |
| 2016 | -23.67% 464/605 |
- - |
- - |
- - |
- - |
| 2015 | 54.31% 15/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中信保诚中证TMT(LOF)A VS. 长安沪深300非周期A(740101) |